Lophius Biosciences GmbH, a Regensburg, Germany-based biotech company, raised a further €2.2m closing its latest financing round at €7.4m.
The round was led by VRD GmbH, one of the current main investors, supported by the Bavarian Growth Fund of Bayern Kapital GmbH and the private investor Wolf Biotech GmbH.
The company will use the extended funding to accelerate the diagnostic developments in the tuberculosis (TB) area to further leverage the potential of its T cell and immunodiagnostic technology platforms and to continue to strengthen its commercialization activities for the CE-marked in vitro diagnostic solution T-Track® CMV to personalize the antiviral Cytomegalovirus (CMV) therapy in transplant patients.
Led by Bernd Merkl, CEO and Managing Director, Lophius Biosciences focuses on the development and marketing of innovative T cell-based diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.
The company recently completed its proof of concept study for the differential diagnosis of tuberculosis based on its proprietary Reverse T Cell Technology (RTT) platform, which enables the differentiation of active T cells versus T memory cells and hence, in the case of TB, allows the identification of patients with a contagious active disease and individuals having a latent infection.